Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

162 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Beyond the Prognostic Value of 2-[18F]FDG PET/CT in Prostate Cancer: A Case Series and Literature Review Focusing on the Diagnostic Value and Impact on Patient Management.
Borea R, Favero D, Miceli A, Donegani MI, Raffa S, Gandini A, Cremante M, Marini C, Sambuceti G, Zanardi E, Morbelli S, Fornarini G, Rebuzzi SE, Bauckneht M. Borea R, et al. Among authors: zanardi e. Diagnostics (Basel). 2022 Feb 24;12(3):581. doi: 10.3390/diagnostics12030581. Diagnostics (Basel). 2022. PMID: 35328134 Free PMC article. Review.
Role of Baseline and Post-Therapy 18F-FDG PET in the Prognostic Stratification of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223.
Bauckneht M, Capitanio S, Donegani MI, Zanardi E, Miceli A, Murialdo R, Raffa S, Tomasello L, Vitti M, Cavo A, Catalano F, Mencoboni M, Ceppi M, Marini C, Fornarini G, Boccardo F, Sambuceti G, Morbelli S. Bauckneht M, et al. Among authors: zanardi e. Cancers (Basel). 2019 Dec 20;12(1):31. doi: 10.3390/cancers12010031. Cancers (Basel). 2019. PMID: 31861942 Free PMC article.
Opportunistic skeletal muscle metrics as prognostic tools in metastatic castration-resistant prostate cancer patients candidates to receive Radium-223.
Bauckneht M, Lai R, D'Amico F, Miceli A, Donegani MI, Campi C, Schenone D, Raffa S, Chiola S, Lanfranchi F, Rebuzzi SE, Zanardi E, Cremante M, Marini C, Fornarini G, Morbelli S, Piana M, Sambuceti G. Bauckneht M, et al. Among authors: zanardi e. Ann Nucl Med. 2022 Apr;36(4):373-383. doi: 10.1007/s12149-022-01716-w. Epub 2022 Jan 19. Ann Nucl Med. 2022. PMID: 35044592 Free PMC article.
Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives.
Rebuzzi SE, Rescigno P, Catalano F, Mollica V, Vogl UM, Marandino L, Massari F, Pereira Mestre R, Zanardi E, Signori A, Buti S, Bauckneht M, Gillessen S, Banna GL, Fornarini G. Rebuzzi SE, et al. Among authors: zanardi e. Cancers (Basel). 2022 Feb 28;14(5):1245. doi: 10.3390/cancers14051245. Cancers (Basel). 2022. PMID: 35267553 Free PMC article. Review.
Oligometastatic Prostate Cancer Treated with Metastasis-Directed Therapy Guided by Positron Emission Tomography: Does the Tracer Matter?
Lanfranchi F, Belgioia L, Marcenaro M, Zanardi E, Timon G, Riondato M, Giasotto V, Zawaideh JP, Tomasello L, Mantica G, Piol N, Borghesi M, Traverso P, Satragno C, Panarello D, Scaffidi C, Romagnoli A, Rebuzzi SE, Coco A, Spina B, Morbelli S, Sambuceti G, Terrone C, Barra S, Fornarini G, Bauckneht M. Lanfranchi F, et al. Among authors: zanardi e. Cancers (Basel). 2023 Jan 3;15(1):323. doi: 10.3390/cancers15010323. Cancers (Basel). 2023. PMID: 36612319 Free PMC article.
Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer.
Nuzzo PV, Pederzoli F, Saieva C, Zanardi E, Fotia G, Malgeri A, Rossetti S, Valenca Bueno L, Andrade LMQS, Patrikidou A, Mestre RP, Modesti M, Pignata S, Procopio G, Fornarini G, De Giorgi U, Russo A, Francini E; SPARTACUSS Investigators. Nuzzo PV, et al. Among authors: zanardi e. J Transl Med. 2023 Feb 3;21(1):75. doi: 10.1186/s12967-022-03861-2. J Transl Med. 2023. PMID: 36737752 Free PMC article.
The Role of mpMRI in the Assessment of Prostate Cancer Recurrence Using the PI-RR System: Diagnostic Accuracy and Interobserver Agreement in Readers with Different Expertise.
Bergaglio C, Giasotto V, Marcenaro M, Barra S, Turazzi M, Bauckneht M, Casaleggio A, Sciabà F, Terrone C, Mantica G, Borghesi M, Signori A, Spina B, Piol N, Zanardi E, Fornarini G, Zawaideh JP; Uro-Oncology Disease Management Team (DMT) of the IRCCS Ospedale Policlinico San Martino Genoa, Italy. Bergaglio C, et al. Among authors: zanardi e. Diagnostics (Basel). 2023 Jan 20;13(3):387. doi: 10.3390/diagnostics13030387. Diagnostics (Basel). 2023. PMID: 36766492 Free PMC article.
Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer.
Nuzzo PV, Ravera F, Saieva C, Zanardi E, Fotia G, Malgeri A, Rossetti S, Valença LB, Oliveira TM, Vauchier C, Pereira Mestre R, Modesti M, Patrikidou A, Pignata S, Procopio G, Fornarini G, De Giorgi U, Russo A, Francini E. Nuzzo PV, et al. Among authors: zanardi e. Ther Adv Med Oncol. 2023 Mar 3;15:17588359231156147. doi: 10.1177/17588359231156147. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 36895852 Free PMC article.
162 results